Tscan Therapeutics is trading 5.87% down at $0.30 on October 5, 2026, and the reason for the decline remains unclear. - No new company announcement was listed for October 5; the latest listed press release was the September 2 strategic reorganization. - Recent filings include October 2 insider ownership statements. - The broader market is mixed, with the Nasdaq up. No reliable source identified a specific catalyst or trading-volume explanation.